allogeneic crispr-edited anti-cll-1 car-t cells cb-012 vs nkx101
| allogeneic crispr-edited anti-cll-1 car-t cells cb-012 | nkx101 | |
|---|---|---|
| Developers | 0 | 1 |
| Clinical trials | 0 | 0 |
| FDA decisions | 0 | 0 |
| Generic name | Allogeneic CRISPR-edited Anti-CLL-1 CAR-T Cells CB-012 | — |
| allogeneic crispr-edited anti-cll-1 car-t cells cb-012 | nkx101 | |
|---|---|---|
| Developers | 0 | 1 |
| Clinical trials | 0 | 0 |
| FDA decisions | 0 | 0 |
| Generic name | Allogeneic CRISPR-edited Anti-CLL-1 CAR-T Cells CB-012 | — |